Andrea Newkirk

what types of investments are needed to prepare for commercialization, maybe particularly with respect to your sales force infrastructure

how are you thinking about the potential for treprostinil to demonstrate an antifibrotic effect there? And what could that then imply for TPIP?

how much does potential MFN legislation factor into your thinking on how to price both in the U.S. and abroad?

can you speak to what trends, if any, that you're picking up on? And when you think about this patient group, how motivated are they to actively seek out

if you could frame for us what you would be considering clinically and commercially meaningful